Biomark to Open a Diagnostic Laboratory in Quebec

Vancouver, British Columbia--(Newsfile Corp. - April 29, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce today that its wholly-owned subsidiary BioMark Diagnostic Solutions Inc. ("BDS") will be operating a diagnostic laboratory in Quebec, Canada, which will primarily serve to advance the clinical validation of its proprietary liquid biopsy platform for early lung cancer detection, monitoring and predicting response to treatment.

The company's aim is to obtain regulatory approval and clinical laboratory licenses to be fully operational in early 2022 and start offering its metabolomics biomarker panel for early lung cancer detection to physicians initially across the Province of Quebec. BioMark's technology alliance with Quebec-based Phytronix Technologies Inc. enhanced its technical capabilities with extensive automated sample preparation and mass spectrometry assay development that prompted the opening of its own diagnostic laboratory.

"This move to Quebec City represents the successful accomplishment of our strategic plan to bring the company to its pre-commercialization stage. The fact that BioMark is spearheading the commercialization of its assay from its own clinical laboratory in Quebec, Canada and later across North America will certainly create more value for our shareholders," said Rashid Bux, CEO of BioMark.

In conjunction with expanding our infrastructure in Quebec, BioMark is also pleased to report that Dr. Jean-François (Jeff) Haince will be leading our laboratory operation as General Manager for BDS. Rashid Ahmed, President and CEO, says, "We are delighted that Jeff decided to join our management team and lead our operation as he has been instrumental in setting up our lab infrastructure and capacity. Jeff possesses an excellent understanding of the whole value chain and regulatory landscape in the molecular diagnostic field and has played a vital role in the commercialization of two early cancer detection molecular diagnostics. Jeff's experience is poised to propel our transition from being research and development focused to a commercialization driven entity."

About Phytronix Technologies Inc.

Phytronix Technologies Inc. is a privately-owned company based in Québec City, Canada, and was founded in 2000. Phytronix invented and patented the Laser Diode Thermal Desorption (LDTD) technology for mass spectrometry. The company introduced the Luxon Ion Source®, which is the second-generation apparatus based on the patented-LDTD® technology and currently the fastest technology for mass spectrometry. This innovative technology enables ultra-high-speed analysis in less than 4 seconds per sample. The company will provide the optimized internal standards that are necessary for use in clinical settings, along with technical expertise required with high-throughput mass spectrometry.

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor, and assess treatment for cancer early and cost-effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors.

Further information about BioMark is available under its profile on the SEDAR website and on the CSE website

For further information on BioMark, please Contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-370-0779

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events, or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved, or disapproved the content of this press release.

To view the source version of this press release, please visit